Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
TScan Therapeutics, Inc. (TCRX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 8-K Quarterly results
Docs: "TScan Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update Presented preliminary Phase 1 clinical data from heme malignancies trial at the ASGCT 26th Annual Meeting; expect to reach recommended Phase 2 dose for two TCR-T therapy product candidates and report interim data by year-end 2023 Announced FDA clearance of fourth IND for solid tumor program – TSC-200-A0201 targeting HPV16 Closed underwritten public offering with net proceeds of approximately $134.7 million Ended 2Q 2023 with cash and cash equivalents of $208.8 million, which along with $30 million proceeds from Amgen, will fund the Company into 2026 WALTHAM, Mass., Aug 10, 2023 -- TScan Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on the development of T cell receptor-e..."
06/29/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "TScan Therapeutics Announces Transition of Chief Financial Officer"
06/15/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Amendment No. 1 to TScan Therapeutics, Inc. 2021 Equity Incentive Plan",
"Amendment No. 1 to TScan Therapeutics, Inc. 2021 Equity Incentive Plan"
05/31/2023 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Underwriting Agreement",
"Form of Pre-Funded Warrant",
"Opinion of Goodwin Procter LLP",
"TScan Therapeutics Announces Launch of Proposed Public Offering",
"TScan Therapeutics Announces Pricing of $140 Million Public Offering"
05/31/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "TScan Therapeutics Appoints Gavin MacBeath, Ph.D. as Chief Executive Officer and as a Member of the Board of Directors WALTHAM, Mass., May 24 , 2023 — TScan Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on the development of T cell receptor -engineered T cell therapies for the treatment of patients with cancer, today announced that its Board of Directors has appointed Gavin MacBeath, Ph.D., as Chief Executive Officer of TScan and as a Class I Director of its Board, each effective as of May 24, 2023. Dr. MacBeath, has been serving as acting CEO since March 2023. Dr. MacBeath joined TScan in 2018 and has developed and advanced the Company's scientific platform and clinical programs. Since his appointment as acting CEO, the Company has made great progress across both..."
05/17/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"TScan Therapeutics Presents Preliminary Phase 1 Clinical Results on TSC-100 and TSC-101 at the American Society of Gene & Cell Therapy 26th Annual Meeting"
05/16/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Sales Agreement, by and between TScan Therapeutics, Inc. and Wedbush Securities Inc.",
"Legal Opinion of Goodwin Procter LLP"
05/10/2023 8-K Quarterly results
Docs: "TScan Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update Entered into partnership with Amgen to identify novel targets in Crohn’s disease; TScan to receive $30 million upfront Enrolled patients in all three arms of Phase 1 hematologic malignancies study; TSC-101 progressing to second dose level Announced upcoming trial-in-progress poster presentation on 5/17 at ASGCT, followed by call at 5:30 p.m. ET Appointed Barbara Klencke, M.D., to Board of Directors Ended 1Q 2023 with cash and cash equivalents of $95.6 million, which combined with Amgen partnership extends cash runway into 3Q 2024 WALTHAM, Mass., May 10, 2023 -- TScan Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on the development of T cell receptor -engineered T cell the..."
05/09/2023 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits  Inte...
Docs: "AMGEN AND TSCAN THERAPEUTICS ANNOUNCE COLLABORATION TO IDENTIFY NOVEL TARGETS IN CROHN'S DISEASE Collaboration Brings Together TScan's Proprietary Target Discovery Platform and Amgen's Inflammation Therapeutic Expertise and Research Capabilities TScan to Receive $30 Million Upfront With Potential Development and Commercial Milestone Payments of Over $500 Million"
03/31/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"TSCAN THERAPEUTICS ANNOUNCES CEO TRANSITION"
03/08/2023 8-K Quarterly results
Docs: "TScan Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Upcoming Milestones Phase 1 umbrella trial for TSC-100 and TSC-101 in hematologic malignancies on track to enroll patients into each of the three study arms and provide a clinical update including safety and biomarker data by mid-year 2023 Clearance of primary IND in addition to two INDs for lead TCR-Ts supports concomitant use of multiple TCRs for solid tumor trial; initial data for most advanced TCRs anticipated by year-end 2023 Ended 2022 with cash and cash equivalents of $120.0 million, funding operations into 2Q 2024"
01/23/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"TScan Therapeutics Announces FDA Clearance of Three Investigational New Drug Applications for the Treatment of Solid Tumors"
11/09/2022 8-K Quarterly results
09/12/2022 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
Docs: "Loan and Security Agreement, by and among TScan Therapeutics, Inc., K2 HealthVentures LLC and Ankura Trust Company, LLC †",
"TScan Therapeutics Secures Convertible Debt Facility for up to $60 Million with K2 HealthVentures"
08/10/2022 8-K Quarterly results
07/07/2022 8-K Quarterly results
06/03/2022 8-K Quarterly results
05/31/2022 8-K Quarterly results
05/09/2022 8-K Quarterly results
03/09/2022 8-K Quarterly results
01/24/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-100 for the Treatment of Hematologic Malignancies"
12/02/2021 8-K Quarterly results
11/10/2021 8-K Quarterly results
Docs: "TScan Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Company Progress IND Submissions Expected in Fourth Quarter 2021 for Lead Liquid Tumor TCR-T Therapy Candidates TSC-100 and TSC-101 Lead TCR Identified for TSC-200 Solid-tumor Program Targeting HPV16; TCR Advancing into IND-Enabling Activities with IND Submission Planned for Second Half of 2022 New Solid Tumor Program, TSC-204, Established Based on a TCR Targeting an HLA-C*07:02 Epitope of MAGE-A1 WALTHAM, Mass., November 10, 2021 -- TScan Therapeutics, Inc. , a biopharmaceutical company focused on the development of T-cell receptor engineered T cell therapies for the treatment of patients with cancer, today reported financial results for the quarter ended September 30, 2021, highlighted recent program pr..."
08/19/2021 8-K Quarterly results
Docs: "TScan Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress Debuted as Publicly Traded Company and Raised $100 Million in Gross Proceeds to Fund Liquid and Solid Tumor Programs"
07/20/2021 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy